TW200716122A - Combination for the therapy of benign prostatic hyperplasia - Google Patents

Combination for the therapy of benign prostatic hyperplasia

Info

Publication number
TW200716122A
TW200716122A TW095112920A TW95112920A TW200716122A TW 200716122 A TW200716122 A TW 200716122A TW 095112920 A TW095112920 A TW 095112920A TW 95112920 A TW95112920 A TW 95112920A TW 200716122 A TW200716122 A TW 200716122A
Authority
TW
Taiwan
Prior art keywords
benign prostatic
prostatic hyperplasia
therapy
combination
inhibitor
Prior art date
Application number
TW095112920A
Other languages
English (en)
Chinese (zh)
Inventor
Helmut Haning
Peter Serno
Erwin Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of TW200716122A publication Critical patent/TW200716122A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095112920A 2005-04-13 2006-04-12 Combination for the therapy of benign prostatic hyperplasia TW200716122A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (de) 2005-04-13 2005-04-13 Kombination zur Therapie bei benigner Prostatahyperplasie

Publications (1)

Publication Number Publication Date
TW200716122A true TW200716122A (en) 2007-05-01

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095112920A TW200716122A (en) 2005-04-13 2006-04-12 Combination for the therapy of benign prostatic hyperplasia

Country Status (22)

Country Link
EP (1) EP1888075A1 (pt)
JP (1) JP2008535877A (pt)
KR (1) KR20080007252A (pt)
CN (1) CN101193638A (pt)
AR (1) AR053575A1 (pt)
AU (1) AU2006233567A1 (pt)
BR (1) BRPI0610634A2 (pt)
CA (1) CA2605224A1 (pt)
CR (1) CR9427A (pt)
DE (1) DE102005016981A1 (pt)
DO (1) DOP2006000074A (pt)
GT (1) GT200600145A (pt)
IL (1) IL186604A0 (pt)
MA (1) MA29683B1 (pt)
MX (1) MX2007012567A (pt)
PE (1) PE20061338A1 (pt)
RU (1) RU2007141518A (pt)
SV (1) SV2008002477A (pt)
TN (1) TNSN07385A1 (pt)
TW (1) TW200716122A (pt)
UY (1) UY29473A1 (pt)
WO (1) WO2006108519A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
EP1968705A1 (en) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
RU2009103660A (ru) * 2006-07-07 2010-08-20 Тева Фармасьютикал Индастриес Лтд. (Il) Твердые фармацевтические композиции, включающие тадалафил и по меньшей мере один носитель
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US8729100B2 (en) 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
CA2709104C (en) 2007-12-13 2017-06-13 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US8885621B2 (en) 2010-04-26 2014-11-11 Intel Corporation Method, apparatus and system for switching traffic streams among multiple bands
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
RU2672573C2 (ru) * 2013-06-28 2018-11-16 Ханми Фарм. Ко., Лтд. Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
KR20150056443A (ko) * 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
MY181172A (en) * 2014-06-30 2020-12-21 Hanmi Pharm Ind Co Ltd Composite preparation comprising active ingredient-containing film coating layer
PL3150201T3 (pl) * 2014-06-30 2020-09-21 Hanmi Pharm. Co., Ltd. Preparat kompozytowy zawierający błonową warstwę powlekającą zawierającą inhibitor 5-reduktazy i sposób wytwarzania preparatu kompozytowego
BR112016030731A2 (pt) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd Preparação de compósito, e, método de preparação de uma preparação de compósito
ES2923438T3 (es) * 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
MX2018011642A (es) * 2016-03-31 2019-03-14 Hanmi Pharm Ind Co Ltd Preparacion en capsula compuesta que contiene tadalafilo y tamsulosina con estabilidad y tasa de elucion mejoradas.
KR101835506B1 (ko) * 2016-10-25 2018-03-07 주식회사 에스텍파마 두타스테리드와 타다라필을 함유하는 속효성 복합정제
CN108066347B (zh) * 2016-11-16 2021-02-02 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
KR20080007252A (ko) 2008-01-17
CN101193638A (zh) 2008-06-04
AR053575A1 (es) 2007-05-09
WO2006108519A1 (de) 2006-10-19
CR9427A (es) 2007-12-17
JP2008535877A (ja) 2008-09-04
UY29473A1 (es) 2006-11-30
CA2605224A1 (en) 2006-10-19
RU2007141518A (ru) 2009-05-20
MA29683B1 (fr) 2008-08-01
SV2008002477A (es) 2008-02-08
MX2007012567A (es) 2007-12-10
IL186604A0 (en) 2008-01-20
DOP2006000074A (es) 2006-10-15
BRPI0610634A2 (pt) 2010-07-13
GT200600145A (es) 2007-04-10
DE102005016981A1 (de) 2006-10-19
EP1888075A1 (de) 2008-02-20
AU2006233567A1 (en) 2006-10-19
PE20061338A1 (es) 2007-01-28
TNSN07385A1 (en) 2009-03-17

Similar Documents

Publication Publication Date Title
TNSN07385A1 (en) Therapeutic combination in case of benign prostate hyperplasia
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
DE602006014848D1 (de) Pyrazolopyrimidine als inhibitoren von cyclinabhän
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
LUC00011I2 (pt)
SG164368A1 (en) Treatment of cancer
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
NO20090610L (no) Faste preparater omfattende tadalafil og minst en baerer
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
MXPA05004290A (es) Formulaciones de l-arginina de liberacion sostenida, y metodos para su fabricacion y uso.
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
TW200612919A (en) Lonidamine analogues and their use in male contraception and cancer treatment
TW200621236A (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
WO2006028524A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
SI1830833T1 (sl) Kombinacija inhibitorja glicinskega transporterja GlyT in antipsihotika za zdravljenje simptomovshizofrenije in tudi njena priprava in njena uporaba